amyris inc (AMRS) Key Developments
Amyris, Inc. to Amend its Certificate of Incorporation
Apr 14 14
Amyris, Inc. in its AGM to be held on May 12, 2014, proposed an amendment to its certificate of incorporation to increase the number of total authorized shares from 205,000,000 shares to 305,000,000 shares and the number of authorized shares of common stock from 200,000,000 shares to 300,000,000 shares.
Amyris to Begin Selling Biofene Online
Apr 4 14
Amyris, Inc. announced it has begun selling Biofene(R), Amyris's brand of farnesene, a long-chain branched hydrocarbon, online at farnesene.net. By making initial quantities of its building block molecule available to a broader audience, Amyris seeks to expand Biofene's use beyond the commercial applications the Company and its partners are already developing. Amyris is now selling Biofene through its website in 1 kilogram lot sizes (about a quarter of a gallon). Biofene (trans-beta-Farnesene, E, E-Farnesene, CAS 18794-84-8) is a 15 carbon, long-chain, branched, unsaturated hydrocarbon manufactured by the fermentation of plant-sugars using Amyris's engineered microbes. Biofene offers unique physical properties and chemical reactivity for new materials and for a variety of applications, including adhesives, surfactants, resins, coatings, vitamin precursors, performance materials and crop protection. Farnesene is an essential oil that is found in small quantities in some plants such as apples, but Amyris has developed a proprietary technology to produce farnesene at industrial scale.
Amyris, Inc. and BASF SE Reach Agreement for Strain Engineering Collaboration
Apr 3 14
Amyris, Inc. announced that it is entering into a collaborative research and development agreement with BASF SE. Under the agreement, Amyris will use its strain engineering technology to develop a microorganism capable of producing a target molecule identified by BASF. Based on success of the initial development program, the companies expect to collaborate further on a strain development program and consider other joint research and development opportunities. The companies have agreed not to disclose any details of the agreement.
Amyris and Kuraray Expand Collaboration in Farnesene-Based Polymers
Mar 31 14
Amyris and Kuraray Co. Ltd. announced the expansion and extension of their ongoing collaboration in high performance polymers using Biofene®, Amyris's brand of renewable farnesene. Under the transaction agreements, the parties have extended the duration of the research and development portion of their collaboration for at least two more years. The parties also reaffirmed their commercialization goals by expanding types of, and fields of use for, Kuraray polymer products containing Biofene. As detailed in the agreement, Amyris will receive an undisclosed amount of collaboration funding over the next two years, and Kuraray will purchase approximately $4 million of Amyris's common stock in April of this year.
Amyris, Inc. announced delayed annual 10-K filing
Mar 18 14
On 03/18/2014, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.